PMID- 29468058
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 8
IP  - 3
DP  - 2018 Mar
TI  - A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: 
      Decision making on the eligibility of transplantation.
PG  - 449-452
LID - 10.3892/mco.2017.1542 [doi]
AB  - Absence of neoplastic disease in the organ-recipient is required in order to 
      allow organ transplantation. Due to its rarity, no data regarding management of 
      patients with Multiple endocrine neoplasia type 1 (MEN1) and end-stage renal 
      failure candidates for kidney transplantation are available. A 36 year-old man 
      was referred to the present hospital with MEN1, with a neuroendocrine pancreatic 
      tumor and primary hyperparathyroidism and associated Alport syndrome with end 
      stage renal failure. The present study aimed to establish the eligibility of the 
      patient for a kidney transplantation. The neuroendocrine tumor had been treated 
      with duodenopancreatectomy two years earlier and hyperparathyroidism by 
      parathyroidectomy. The review of the literature did not provide data regarding 
      the eligibility for kidney transplantation of patients harboring a neuroendocrine 
      pancreatic tumor in the context of MEN1. Due to the end-stage renal failure, 
      neuroendocrine markers were unreliable and the investigation therefore relied on 
      imaging studies, which were unremarkable. Young age, low-grade tumor, low 
      expression of Ki67, absence of metastatic lymph nodes, onset in the setting of a 
      MEN1 were all positive prognostic factors of the neuroendocrine tumor. Normal 
      serum calcium ruled out persistent primary hyperparathyroidism. Overall, 
      hemodyalisis is known to significantly reduce life expectancy. Benefits of kidney 
      transplantation overcome the risk of neuroendocrine tumor recurrence in a young 
      patient bearing MEN1.
FAU - Matrone, Antonio
AU  - Matrone A
AD  - Department of Clinical and Experimental Medicine, Unit of Endocrinology I, 
      University of Pisa, I-56124 Pisa, Italy.
FAU - Brancatella, Alessandro
AU  - Brancatella A
AD  - Department of Clinical and Experimental Medicine, Unit of Endocrinology I, 
      University of Pisa, I-56124 Pisa, Italy.
FAU - Marchetti, Piero
AU  - Marchetti P
AD  - Department of Clinical and Experimental Medicine, Division of Metabolism and Cell 
      Transplantation, University of Pisa, I-56124 Pisa, Italy.
FAU - Vasile, Enrico
AU  - Vasile E
AD  - Department of Translational Research and of New Surgical and Medical 
      Technologies, Unit of Oncology, University of Pisa, I-56124 Pisa, Italy.
FAU - Boggi, Ugo
AU  - Boggi U
AD  - Department of Translational Research and of New Surgical and Medical 
      Technologies, Division of General and Transplant Surgery, University of Pisa, 
      I-56124 Pisa, Italy.
FAU - Elisei, Rossella
AU  - Elisei R
AD  - Department of Clinical and Experimental Medicine, Unit of Endocrinology I, 
      University of Pisa, I-56124 Pisa, Italy.
FAU - Cetani, Filomena
AU  - Cetani F
AD  - Department of Clinical and Experimental Medicine, Unit of Endocrinology II, 
      University of Pisa, I-56124 Pisa, Italy.
FAU - Marcocci, Claudio
AU  - Marcocci C
AD  - Department of Clinical and Experimental Medicine, Unit of Endocrinology II, 
      University of Pisa, I-56124 Pisa, Italy.
FAU - Vitti, Paolo
AU  - Vitti P
AD  - Department of Clinical and Experimental Medicine, Unit of Endocrinology I, 
      University of Pisa, I-56124 Pisa, Italy.
FAU - Latrofa, Francesco
AU  - Latrofa F
AD  - Department of Clinical and Experimental Medicine, Unit of Endocrinology I, 
      University of Pisa, I-56124 Pisa, Italy.
LA  - eng
PT  - Journal Article
DEP - 20171229
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC5791425
OTO - NOTNLM
OT  - MEN1
OT  - alport syndrome
OT  - cancer recurrence
OT  - glucagon
OT  - hyperparathyroidism
OT  - neuroendocrine tumor
OT  - transplantation
EDAT- 2018/02/23 06:00
MHDA- 2018/02/23 06:01
PMCR- 2017/12/29
CRDT- 2018/02/23 06:00
PHST- 2017/08/20 00:00 [received]
PHST- 2017/11/28 00:00 [accepted]
PHST- 2018/02/23 06:00 [entrez]
PHST- 2018/02/23 06:00 [pubmed]
PHST- 2018/02/23 06:01 [medline]
PHST- 2017/12/29 00:00 [pmc-release]
AID - MCO-0-0-1542 [pii]
AID - 10.3892/mco.2017.1542 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2018 Mar;8(3):449-452. doi: 10.3892/mco.2017.1542. Epub 2017 Dec 
      29.